Transdermal drug delivery systems (TDDS, TDS) are innovative methods designed to administer medications through the skin, providing a non-invasive alternative to oral and injectable routes. This approach offers several therapeutic advantages, including improved patient compliance and the ability to bypass first-pass metabolism, which can enhance drug bioavailability.

 

Transdermal drug delivery systems, (TDDS, TDS) commonly known as transdermal patches, deliver a controlled amount of medication directly into the bloodstream via the skin. These systems are particularly beneficial for patients who require long-term medication management, as they allow for steady plasma drug levels and reduce the frequency of dosing compared to oral medications.

Transdermal drug delivery systems

Key Features of TDDS

Controlled Release

Transdermal drug delivery systems (TDDS, TDS)  provide a sustained release of medication over extended periods, ranging from hours to days

Ease of Use

They are user-friendly, requiring minimal training for application, which enhances patient adherence

Non-Invasive

This method eliminates the discomfort associated with injections and reduces risks related to needle use

Types of Transdermal Systems

Drug-in-Adhesive Systems (DIA)

These patches consist of an adhesive layer that contains the active ingredient. The drug is released as the adhesive adheres to the skin.

Reservoir
Systems

In these patches, the drug is contained in a separate reservoir, which is released through a rate-controlling membrane upon application.

Matrix
Systems

These involve a matrix that holds the drug and controls its release through diffusion.

Micro-Reservoir Systems

Similar to matrix systems but utilize micro-reservoirs for more controlled release

Required Studies for Development

The development of transdermal systems involves comprehensive studies to ensure safety, efficacy, and regulatory compliance. 

Key studies include:

Physicochemical Characterization

  • Evaluation of the drug’s properties such as solubility, stability, and permeability through skin layers is crucial for selecting suitable candidates for transdermal delivery

Formulation Studies

  • Investigating different formulations helps optimize drug release rates and enhance skin penetration. This includes selecting appropriate excipients and penetration enhancers

In Vitro Permeation Studies

  • These studies assess how well the drug can permeate through skin models, providing insights into expected performance in humans

Clinical Trials

  • Phase I trials typically focus on safety and pharmacokinetics, while later phases evaluate efficacy in target populations. Clinical trials are essential for obtaining regulatory approval from bodies like the FDA, EMA, etc.
  • Adhesion performance studies are mandatory
  • Irritation/Sensitization studies *

*The performance of Irritation/Sensitization studies for Transdermal Drug Delivery Sysstems (TDDS, TDS) are mandatory for US-FDA. In EU the European Medicines Agency (EMA) has established specific guidelines that outline the necessary tests for TDDS. According to these guidelines, irritation and sensitization assessments are required alongside pharmacokinetic evaluations to ensure comprehensive safety profiling whenever an irritiation/sensitization potential cannot be ruled out.

Join Us in Transforming Healthcare!

3S Pharma performs clinical studies for Transdermal Drug Delivery systems (TDS, TDDS) for more than 10 years!

Pharmacokinetic studies alone (Single dose, Multiple dose), Adhesion performance studies as stand alone studies or combuned PK and adhesion performance single dose studies. 3S Pharma also performs for Transdermal Drug Delivery Systems Irritation/Sensitization studies (stand alone).

Contact us now to learn how 3S Pharma can help you navigate the complexities of clinical research for Transdermal Drug Delivery Systems (TDS, TDDS) and bring your innovations to market faster ans safer!

 

3S Pharma - Your Partner in Clinical Excellence.